872332-67-7

Basic information

• Product Name: 3-amino-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide
• CAS NO: 872332-67-7
• Molecular Weight: 420.478
• Mol File: 872332-67-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 3-amino-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide(872332-67-7)
• EPA Substance Registry System: 3-amino-N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methylbenzamide(872332-67-7)

Safety Data

• Hazardous Substances Data: 872332-67-7(Hazardous Substances Data)

Upstream product

• 872332-66-6 N-(4-((4-ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-4-methyl-3-nitrobenzamide 
• 654-70-6 4-amino-2-trifluoromethylbenzonitrile 
• 876322-73-5 4-amino-2-(trifluoromethyl)benzaldehyde 
• 89976-12-5 1-methyl-4-nitro-2-(trifluoromethyl) benzene 
• 859027-20-6 1-ethyl-4-(4-nitro-2-(trifluoromethyl)benzyl)piperazine 
• 694499-22-4 1-(bromomethyl)-4-nitro-2-(trifluoromethyl) benzene 
• 5308-25-8 4-ethylpiperazine 
• 630125-91-6 4-(4-ethylpiperazin-1-ylmethyl)-3-trifluoromethylphenylamine 

Downstream Products

• 1186206-79-0 ALW-II-41-27 

Relevant articles and documents

A Putative Single-Photon Emission CT Imaging Tracer for Erythropoietin-Producing Hepatocellular A2 Receptor

Erythropoietin-producing hepatocellular (Eph) receptors are receptor tyrosine kinases involved in cell-cell contact. The EphA2 receptor is associated with cancer proliferation and migration. Therefore, EphA2 receptor imaging has the potential for cancer d

COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of Abl, Bcr-Abl, Bmx, BTK, b-RAF, c RAF, CSK, cSRC, Fes, FGFR3, Flt3, IKKα, IKKβ, JNK1α1, JNK2α2, Lck, Met, MKK4, MKK6, p70S6K, PAK2, PDGFRα, PKA, PKCα, PKD2, ROCK-II, Ros, Rsk1, SAPK2α, SAPK2β, SAPK3, SAPK4, SGK, Syk, Tie2 and TrkB kinases.